Health Condition 1: N72- Inflammatory disease of cervix uteri Health Condition 2: N61- Inflammatory disorders of breast
Conditions
Interventions
None listed
Sponsors
DrK Satyamoorthy
Eligibility
Inclusion criteria
Inclusion criteria: Subjects diagnosed with breast cancer and undergoing surgery Subjects diagnosed with cervical cancer and undergoing surgery
Exclusion criteria
Exclusion criteria: 1. Patients having any kind of infection 2. Patients having an auto-immune disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Our study can reveal the upstream mechanism(s) responsible for IL-6 secretion which in turn aid in developing targeted blockers to inhibit the secretion of IL-6 from cancer associated fibroblasts at the tumor microenvironment. Identifcation of novel genes regulated by epigenetic changes which can be further targeted for diagnostic/prognostic/therapeutic purposesTimepoint: 5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| The developed in-house IL-6R and gp130 antibodies alone or in combination with the inhibitors for secretory stimulants may have potential anti-cancerous effect by selectively targeting IL-6 signaling pathway. Timepoint: 5years | — |
Countries
India
Contacts
Public ContactDr K Satymoorthy
Manipal School of Life Sciences MAHE
Outcome results
None listed